

REMARKS/ARGUMENTS

In response to the Office Action mailed January 4, 2008, Applicants amend their application and request reconsideration in view of the amendments and the following remarks. In this amendment, Claim 1 is amended, no new claims have been added and claim 5 has been cancelled without prejudice so that Claims 1-4 remain pending. No new matter has been introduced.

Claim 5 was objected to for improper format and has been cancelled without prejudice.

Claims 10-5 were rejected as being anticipated by U.S. Patent Publication No. US2004/0037886 to Hsu. This rejection is respectfully traversed.

Application exists only if all of the elements of the claimed invention are present in a system or method disclosed, expressly or inherently, in a single prior art reference. Therefore, if it can be shown that there is one difference between the claimed invention and what is disclosed in the single reference, there can be no anticipation.

Independent Claim 1 has been amended to have more precise structural limitations. In addition, it is respectfully submitted that the combinations of a rapamycin and 17 beta- estradiol is unique as claimed. As shown in Figure 68, this unique combination is more effective than either drug alone (See paragraphs 278-280 of this present application.) Hsu merely discloses a laundry list and not this specific combination that produces a benefit. Accordingly, reconsideration and withdrawal of the rejection is respectfully requested.

A favorable action on the merits is earnestly solicited.

Respectfully submitted,

/Carl J. Evens/

By: _____
Carl J. Evens
Reg. No. 33,874

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2518
Dated: April 2, 2008